SCHEMBL4187084

SCHEMBL4187084

COc1ccc(-c2nc3ncccc3c(=O)n2NCc2ccc(Br)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
NPSR1 Q6W5P4 4/20 0.56
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
LMNA P02545 5/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 2/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
IDO1 P14902 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
POLB P06746 1/20 0.43
PANK1 Q8TE04 1/20 0.42
PANK3 Q9H999 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199192 0.88 SMN1; SMN2 (0.48) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4188985 0.88 MAPT (0.46) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4199588 0.88 MEN1 (0.49) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4191475 0.81 NPSR1 (0.57) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4187061 0.79 CYP1A2 (0.46) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4199190 0.78 KMT2A (0.49) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4242039 0.78 NPSR1 (0.66) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4238641 0.77 NPSR1 (0.61) MAPTNPSR1CYP1A2CYP3A4CYP2D6
SCHEMBL4202613 0.77 SMN1; SMN2 (0.48) MAPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4205033 0.76 MEN1 (0.47) MAPTNPSR1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 MAPT 4164/4885NPSR1 753/4885CYP1A2 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.